PHOENIX, March 31,
2022 /PRNewswire/ -- Creative Medical Technology
Holdings, Inc. ("Creative Medical Technology" or the "Company")
(NASDAQ: CELZ), a leading commercial stage biotechnology company
focused on a regenerative approach to immunotherapy, urology,
neurology, and orthopedics, today announced that it has signed a
Master Collaboration Agreement with the University of Miami to accelerate development of
the Company's ImmCelz® Supercharged Autologous Immunotherapy
Platform.
ImmCelz®, which is protected by trade secrets and published U.S.
patents, utilizes adult stem cells derived from qualified donors to
endow specific properties to the patient's immune cells. After
the patient's harvested cells are incubated with the Company's
cell-free reprogramming "cocktail", the cells are re-injected back
into the patient. These "supercharged" cells subsequently
"educate" other cells of the immune system to stop attacking the
body, while preserving the ability to attack foreign pathogens.
"This valuable partnership with the University of Miami accelerates the development of
our ImmCelz® platform," said Timothy
Warbington, President and CEO of the Company. "Under the
leadership of Drs. Camillo Ricordi
and Giacomo Lanzoni at the cGMP
Advanced Human Cell and Biologics Manufacturing Facility of the
Cell Transplant Center at the Diabetes Research Institute,
University of Miami Miller School of
Medicine, we will continue to optimize the platform and generate
data required to advance our therapies through clinical
trials."
"Dr. Lanzoni and I are excited to expand our relationship with
Tim and the Creative Medical Technology leadership team to further
the advancement of the ImmCelz® platform," said Dr. Ricordi. "As
previously announced, we already have seen early success,
suggesting the ability of ImmCelz® to achieve superior results
in a pre-clinical, in-vitro model system that should be
amenable to safe, scalable and rapid clinical translation."
"For integration in this Master Collaboration Agreement, a
project proposal and research budget were submitted from the team
at the University of Miami and accepted
by the Company with the goal to begin additional research
immediately. It is our intent to disclose relevant results when
appropriate," Mr. Warbington added.
The Company plans to advance multiple indications for ImmCelz®
starting with stroke, which is currently under FDA review. Upon
successful approval to proceed with clinical trials for stroke, the
Company anticipates accelerating additional therapies under the
ImmCelz® umbrella, including for type I diabetes, heart disease,
liver disease, and kidney disease.
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a commercial stage
biotechnology company specializing in stem cell technology in the
fields of immunotherapy, urology, neurology, and orthopedics. For
further information about the Company, please visit
www.creativemedicaltechnology.com.
Forward Looking Statements
This news release may contain forward-looking statements
including but not limited to comments regarding the timing and
content of upcoming clinical trials and laboratory results,
marketing efforts, funding, etc. Forward-looking statements address
future events and conditions and, therefore, involve inherent risks
and uncertainties. Actual results may differ materially from those
currently anticipated in such statements. See the periodic and
other reports filed by Creative Medical Technology Holdings, Inc.
with the Securities and Exchange Commission and available on the
Commission's website at www.sec.gov.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/creative-medical-technology-signs-master-collaboration-agreement-with-the-university-of-miami-to-accelerate-development-of-immcelz-supercharged-autologous-immunotherapy-platform-301514650.html
SOURCE Creative Medical Technology Holdings, Inc.